Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Google Secures Pentagon AI Deal for Classified Projects 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
ZUG, Switzerland, Feb. 18, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will host a Key Opinion Leader breakfast focused on current advances in acute sensorineural hearing loss (ASNHL) treatment on Friday, February 26, from 8am-9:30am Eastern Time in New York City.
The meeting will feature a keynote presentation by Adrien A. Eshraghi, MD, MSc, FACS, who will discuss the pathophysiology and clinical management of acute sensorineural hearing loss, as well as several members of the Auris Medical executive management team, who will provide an overview of the Company's technology and ongoing clinical development work with AM-111 for the treatment of ASNHL.
To reserve a seat, please contact Mac MacDonald at 212-915-2567 or via e-mail at [email protected]. A live webcast of the event will be available at http://lifesci.rampard.com/20160226/reg.jsp and will be accessible through the Investors section of the Company's website at www.aurismedical.com.
Dr. Eshraghi is the Chief of Otology and Neurotology Clinics at Jackson Memorial Medical Center and Director of the University of Miami Hearing Research Laboratory. He is also a Professor of Otolaryngology and Biomedical Engineering. Dr. Eshraghi has received national and international recognition for his clinical activities, teaching, and research in the field of otolaryngology and neurotology. He has authored more than 100 scientific papers and medical book chapters related to the management of hearing loss and tinnitus. He is a fellow of the American College of Surgeons, American Academy of Otolaryngology-Head and Neck Surgery, and Otology Society. He was elected as President of the Florida Society of Otolaryngology-Head and Neck Surgery in 2015.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Contact: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, [email protected]
HUG#1987156
